Frontage Laboratories unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its campus in Exton, Pennsylvania.
The event marked the official launch of 46,300-square-foot Good Manufacturing Practice (GMP) facility located at 240 Sierra Drive. This expansion enhances Frontage's CRDMO footprint and reinforces its commitment to accelerating pharmaceutical and biotech innovation. This facility includes nine (9) GMP suites: two (2) high-potent suites, two (2) aseptic suites, and five (5) non-sterile suites, supporting manufacturing for injectables, tablets, capsules, creams, gels, ointments, ophthalmic and nasal preparations. This building also houses two (2) formulation development labs, and three (3) analytical labs including a micro lab. It provides a comprehensive, one-stop-shop solution for pharmaceutical and biotech clients covering all aspects of clinical supplies, including formulation development, manufacturing, analytical testing, packaging, labelling, distribution, and storage.
This expansion complements Frontage's existing service offerings, which include drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support.
"We are grateful to all who joined us to share in our joyous occasion. The grand opening of this new CRDMO marks a significant milestone for us in the CDMO and clinical trial material supply space," said Dr. Song Li, Founder and Executive Chairman of Frontage. Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, added, "For years, Frontage has been expanding by opening new sites and acquiring existing ones. The launch of our new state-of-the-art CDMO facility significantly enhances our manufacturing capabilities, positioning us closer to our clients and enabling us to respond more efficiently to their evolving development and supply needs."